Svenska

CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate: CVnCoV

Report this content
  • WACKER SUPPORTS CUREVAC IN THE PRODUCTION OF ITS MRNA-BASED VACCINE CANDIDATE AGAINST COVID-19
  • MANUFACTURING AT WACKER´S BIOTECH SITE IN AMSTERDAM IS SCHEDULED TO START IN THE FIRST HALF OF 2021

För mer information se bifogad pressrelease.

Prenumerera

Dokument & länkar